Skyee Receives In-Principle Approval (IPA) for Major Payment Institution License (MPI) from the Monetary Authority of Singapore (MAS)

2025-01-13 IDOPRESS

SINGAPORE,Jan. 13,2025 -- Skyee Pte. Ltd. ("Skyee") is excited to announce that it has been granted In-Principle Approval (IPA) for the Major Payment Institution (MPI) license from the Monetary Authority of Singapore (MAS). Skyee is a wholly owned subsidiary of Skyee Group a Chinese leading cross border payment solution provider in China,Europe,North America and North Asia. If obtained,the MPI license will allow Skyee to service its Singapore market,further enhancing the payment experience for cross-border sellers,streamlining payment processing,increasing efficiency,and reducing operational costs through Account Issuance,Domestic Money Transfer,Cross-border Money Transfer,Merchant Acquisition,and e-Money services.

Skyee Group,established in 2016,has consistently adhered to its mission of "linking the global financial network,building a new payment system,and providing all-around convenience for cross-border fund transfers." Skyee's receipt of the IPA from MAS underscores its strong reputation as a responsible digital financial technology company. By continuously optimizing its products and services,Skyee Group has secured strategic investment from Lakala Payment Group,China's first A-share listed third-party payment company,and has become a member of its group.

Kozen Tan,CEO of Skyee Singapore has spearheaded and actively drive the acquisition of this license and stated,"Being granted this IPA from the Monetary Authority of Singapore is a big milestone for Skyee,especially as we expand our reach and payment services across geographical borders,solidifying our position in one of the most significant financial markets globally".

This announcement follows Skyee Group track record and contributions to the emerging internet-based global financial system,further cementing its position as a trusted and well-regulated operator.

About Skyee: Based in Guangzhou,China,Skyee is a cross-border payment technology company with offices in Hangzhou,Shenzhen,Hong Kong,Singapore,Los Angeles,London,Tokyo,and Canada. Dedicated to providing innovative payment solutions for users with cross-border funding needs. Skyee offers safe and convenient global cross-border payment services for various sizes of overseas merchants through its self-developed payment platform. Skyee provides personalized solutions for more than twenty global payment scenarios to enhance payment efficiency and user experience,meeting diverse payment needs.

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

Newest

1Cangxi County Holds 2026 New Year's Cultural Performance for the Public

Cangxi County Holds 2026 New Year's Cultural Performance for the Public

2The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

3The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

4Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

5Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

6Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

©copyright 2009-2020 Singapore Info Map